

# The unfavorable effects of COVID-19 on Dutch advanced melanoma care

Olivier J. Van Not MD, Jesper van Breeschoten PharmD, Alfonsus J.M. van den Eertwegh MD, PhD, Doranne L. Hilarius PharmD, PhD, Melissa M. De Meza MD, John B. Haanen MD, PhD, Christian U. Blank MD, PhD, Maureen J.B. Aarts MD, PhD, Franchette W.P.J. van den Berkmortel MD, PhD, Jan Willem B. de Groot MD, PhD, Geke A.P. Hospers MD, Ph, Rawa K. Ismail PharmD, Ellen Kapiteijn MD, PhD, Djura Piersma MD, PhD, Rozemarijn S. van Rijn MD, PhD, Marion A.M. Stevense-den Boer MD, PhD, Astrid A.M. van der Veldt MD, PhD, Gerard Vreugdenhil MD, PhD, Marye J. Boers-Sonderen MD, PhD, Willeke A.M. Blokx MD, PhD, Karijn P.M. Suijkerbuijk MD, PhD and Michel W.J.M. Wouters MD, PhD

## Table of contents

Supplementary tables .....	2
Supplement I – Baseline characteristics first wave .....	2
Supplement II – Baseline characteristics second wave .....	3
Supplement III – Baseline characteristics (regions).....	4

## Supplementary tables

### Supplement I – Baseline characteristics first wave

Comparison of baseline characteristics of patients diagnosed during the first wave (March 16<sup>th</sup> 2020 until May 24<sup>th</sup> 2020) vs. the control period (March 16<sup>th</sup> 2018 until May 24<sup>th</sup> 2018 and March 16<sup>th</sup> 2019 until May 24<sup>th</sup> 2019).

Baseline variable		First wave (N = 108)	Control period (N = 339)	P-value
Age, median (range)		69 (36-94)	68 (21-92)	0.599
Gender	Male	60 (55.6)	199 (58.7)	0.642
	Female	48 (44.4)	140 (41.3)	
ECOG PS	0-1	79 (82.3)	259 (85.5)	0.553
	≥2	17 (17.7)	44 (14.5)	
LDH	Not determined/normal	54 (54.0)	195 (60.9)	0.427
	250-500U/L	29 (29.0)	83 (25.9)	
	>500 U/L	17 (17.0)	42 (13.1)	
Stage (8 <sup>th</sup> edition AJCC)	Unresectable IIIc	13 (12.3)	34 (10.1)	0.900
	IV-M1a	8 (7.5)	31 (9.2)	
	IV-M1b	11 (10.4)	38 (11.3)	
	IV-M1c	39 (36.8)	133 (39.5)	
	IV-M1d	35 (33.0)	101 (30.0)	
Brain metastases	No	68 (66.0)	225 (69.0)	0.839
	Yes, asymptomatic	13 (12.6)	36 (11.0)	
	Yes, symptomatic	22 (21.4)	65 (19.9)	
Liver metastases	No	74 (70.5)	244 (73.5)	0.631
	Yes	31 (29.5)	88 (26.5)	
Organ sites	0-2	64 (59.3)	200 (59.0)	1.000
	≥3	44 (40.7)	139 (41.0)	
BRAF <sup>V600</sup> -mutation	Wild-type	66 (61.1)	179 (52.8)	0.162
	Mutant	42 (38.9)	160 (47.2)	
Region	North	15 (13.9)	74 (21.8)	0.175
	Middle	65 (60.2)	178 (52.5)	
	South	28 (25.9)	87 (25.7)	

## Supplement II – Baseline characteristics second wave

Comparison of baseline characteristics of patients diagnosed during the second wave (September 21<sup>st</sup> 2020 until December 27<sup>th</sup> 2020) vs. the control period (September 21<sup>st</sup> 2018 until December 27<sup>th</sup> 2018 and September 21<sup>st</sup> 2019 until December 27<sup>th</sup> 2019).

Baseline variable		Second wave (N = 166)	Control period (N = 455)	P-value
Age, median (range)		68 (27-91)	66 (24-92)	0.215
Gender	Male	97 (58.4)	269 (59.1)	0.951
	Female	69 (41.6)	186 (40.9)	
ECOG PS	0-1	109 (72.2)	351 (84.4)	0.002
	≥2	42 (27.8)	65 (15.6)	
LDH	Not determined/normal	77 (50.0)	255 (59.7)	0.091
	250-500U/L	48 (31.2)	100 (23.4)	
	>500 U/L	29 (18.8)	72 (16.9)	
Stage (8 <sup>th</sup> edition AJCC)	Unresectable IIIc	9 (5.5)	49 (10.8)	0.001
	IV-M1a	5 (3.1)	36 (8.0)	
	IV-M1b	24 (14.7)	44 (9.7)	
	IV-M1c	59 (36.2)	196 (43.4)	
	IV-M1d	66 (40.5)	127 (28.1)	
Brain metastases	No	94 (58.8)	309 (70.9)	0.016
	Yes, asymptomatic	29 (18.1)	62 (14.2)	
	Yes, symptomatic	37 (23.1)	65 (14.9)	
Liver metastases	No	103 (64.0)	313 (69.7)	0.214
	Yes	58 (36.0)	136 (30.3)	
Organ sites	0-2	94 (56.6)	258 (56.7)	1.000
	≥3	72 (43.4)	197 (43.3)	
BRAF <sup>V600</sup> -mutation	Wild-type	87 (52.4)	221 (48.6)	0.450
	Mutant	79 (47.6)	234 (51.4)	
Region	North	33 (19.9)	90 (19.8)	0.794
	Middle	102 (61.4)	266 (58.5)	
	South	31 (18.7)	98 (21.5)	

### Supplement III – Baseline characteristics (regions)

Comparison of baseline characteristics of patients diagnosed in the three different regions defined in this study during the first wave.

Baseline variable		North (N = 15)	Middle (N = 65)	South (N = 28)	P-value
Age, median (range)		72 (45-87)	69 (36-94)	65.5 (40-91)	0.472
Gender	Male	9 (60.0)	36 (55.4)	15 (53.6)	0.921
	Female	6 (40.0)	29 (44.6)	13 (46.4)	
ECOG PS	0-1	12 (85.7)	49 (81.7)	18 (81.8)	0.936
	≥2	2 (14.3)	11 (18.3)	4 (18.2)	
LDH	Not determined/normal	8 (61.5)	35 (57.4)	11 (42.3)	0.305
	250-500U/L	5 (38.5)	15 (24.6)	9 (34.6)	
	>500 U/L	0 (0.0)	11 (18.0)	6 (23.1)	
Stage (8 <sup>th</sup> edition AJCC)	Unresectable IIIc	2 (13.3)	9 (14.3)	2 (7.1)	0.278
	IV-M1a	3 (20.0)	4 (6.3)	1 (3.6)	
	IV-M1b	1 (6.7)	4 (6.3)	6 (21.4)	
	IV-M1c	4 (26.7)	24 (38.1)	11 (39.3)	
	IV-M1d	5 (33.3)	22 (34.9)	8 (28.6)	
Brain metastases	No	10 (66.7)	40 (64.5)	18 (69.2)	0.995
	Yes, asymptomatic	2 (13.3)	8 (12.9)	3 (11.5)	
	Yes, symptomatic	3 (20.0)	14 (22.6)	5 (19.2)	
Liver metastases	No	12 (80.0)	44 (71.0)	18 (64.3)	0.555
	Yes	3 (20.0)	18 (29.0)	10 (35.7)	
Organ sites	0-2	9 (60.0)	40 (61.5)	15 (53.6)	0.772
	≥3	6 (40.0)	25 (38.5)	13 (46.4)	
BRAF <sup>V600</sup> -mutation	Wild-type	10 (66.7)	39 (60.0)	17 (60.7)	0.891
	Mutant	5 (33.3)	26 (40.0)	11 (39.3)	